soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Emily Kronau, PharmD, MBA (@Phar_em_D)
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 13 - Aug 18


















:max_bytes(150000):strip_icc()/insulin-injection-478185779-594b3cae3df78cae8111498f.jpg)
%20(1).png)





